NASDAQ:CCXI
Delisted
ChemoCentryx Stock News
$51.99
+0 (+0%)
At Close: Jan 27, 2023
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
08:30am, Monday, 16'th May 2022
SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. W
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the p
ChemoCentryx: A Biotech Stock Well Worth the Risk
04:00am, Monday, 09'th May 2022
In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an important inflection point for a stock that had been in a
ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates
05:18pm, Friday, 06'th May 2022
ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow five-fold from the previous quarter's levels.
Why ChemoCentryx Shares Are Popping Off
11:33am, Friday, 06'th May 2022
ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results. ChemoCentryx reported quarterly losses of 55 cents per share which misse
ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q1 2022 Results - Earnings Call Transcript
08:35pm, Thursday, 05'th May 2022
ChemoCentryx, Inc. (NASDAQ:CCXI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Dr. Thomas Schall – Chairman, President and Chief Executive Officer Tausif Butt – Exe
ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates
08:19pm, Thursday, 05'th May 2022
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
08:30am, Thursday, 28'th Apr 2022
SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close o
Why Is ChemoCentryx (CCXI) Up 1.8% Since Last Earnings Report?
12:47pm, Thursday, 31'st Mar 2022
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?
2 Stocks Down 30% in 2022 That Are Great Buys Right Now
11:30am, Wednesday, 30'th Mar 2022
Years from now you could be thanking yourself for buying shares of these two companies today.
Bonds Are Screaming “Recession.” That's Great News For One Top Sector.
04:44pm, Tuesday, 29'th Mar 2022
The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.
Is ChemoCentryx, Inc. (CCXI) A Great Long-Term Investment?
01:43pm, Monday, 07'th Mar 2022 Insider Monkey
Wasatch Global Investors, an investment management firm, published its "Wasatch Micro Cap Fund" fourth quarter 2021 investor letter – a copy of which can be downloaded here.
ChemoCentryx, Inc. 2021 Q4 - Results - Earnings Call Presentation
09:11pm, Friday, 04'th Mar 2022 Seeking Alpha
ChemoCentryx: Good Post-Approval Performance, But Needs More Time
07:06pm, Thursday, 03'rd Mar 2022 Seeking Alpha
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ChemoCentryx, Inc. with Losses of $100,000 to Contact the Firm
11:30pm, Wednesday, 02'nd Mar 2022 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $CCXI #CCXI--The Schall Law Firm Encourages Investors in ChemoCentryx, Inc. with Losses of $100,000 to Contact the Firm
